Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06111339 · ClinicalTrials.gov registry record · Phase 2

Ketamine for OUD and Suicidal Ideation in the ED

A Phase 2 study, sponsored by Brigham and Women's Hospital.

Terminated
Registry status
Phase 2
Development phase
4
Enrollment target

NCT06111339 is a Phase 2 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 4 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06111339, a Phase 2 study, was terminated before completion, sponsored by Brigham and Women's Hospital.

TERMINATED
Registry status
Phase 2
Development phase
4 participants
Enrollment target

Study Summary

This is a pilot, double-blind, placebo-controlled randomized clinical trial of individuals with opioid use disorder (OUD) with suicidal ideation in the emergency department (ED) to receive either a single infusion of ketamine 0.8mg/kg (n=25) or saline placebo (n=25). The primary aim is to evaluate the safety of the ketamine treatment. The secondary aim is to determine the preliminary efficacy of opioid- and suicide-related outcomes.

Interventions

  • DRUG Ketamine
  • OTHER Saline Solution

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2024-06-14
Est. Completion 2025-03-31
Phase Phase 2

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT06111339

The ClinicalTrials.gov registry entry for NCT06111339 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.

NCT06111339 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06111339 about?

NCT06111339 is a clinical study titled "Ketamine for OUD and Suicidal Ideation in the ED". This is a pilot, double-blind, placebo-controlled randomized clinical trial of individuals with opioid use disorder (OUD) with suicidal ideation in the emergency department (ED) to receive either a single infusion of ketamine 0.8mg/kg (n=25) or saline placebo (n=25). The primary aim is to evaluate t...

What is the current status of trial NCT06111339?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2024-06-14. Estimated completion is 2025-03-31.

What interventions are being tested in trial NCT06111339?

The interventions under investigation include: Ketamine (DRUG), Saline Solution (OTHER).

Who is sponsoring clinical trial NCT06111339?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.